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Prevention of pure red cell aplasia after major or bidirectional
ABO blood group incompatible hematopoietic stem cell
transplantation by pretransplant reduction of host anti-donor
isoagglutinins
Abstract
BACKGROUND: Persistent anti-donor isoagglutinins after major ABO blood group incompatible
hematopoietic stem cell transplantation may cause delayed red blood cell engraftment and
post-transplant pure red cell aplasia. DESIGN AND METHODS: We investigated the effect of
pretransplant anti-donor isoagglutinin reduction by in vivo absorption and/or plasmapheresis on the
incidence of pure red cell aplasia and the time to red blood cell engraftment in 153 hematopoietic stem
cell transplant recipients with major ABO incompatibility. RESULTS: Twelve patients (8%) developed
pure red cell aplasia, 3/98 (3%) with, and 9/55 (16%) without prior isoagglutinin reduction (p=0.009).
Red blood cell engraftment was faster in patients with isoagglutinin reduction; in addition, peripheral
blood hematopoietic stem cell transplantation, acute graft-versus-host disease, and younger age were
associated with faster red blood cell engraftment in Cox regression analysis. In patients with pure red
cell aplasia the mean red blood cell engraftment occurred after 225 days (p<0.001) and was associated
with a simultaneous decrease of anti-donor isoagglutinins. Patients with pure red cell aplasia had higher
pretransplant anti-donor isoagglutinin titers (p=0.001) and received more post-transplant red blood cell
transfusions (p<0.001). CONCLUSIONS: Following major ABO incompatible hematopoietic stem cell
transplantation, pure red cell aplasia and delayed red blood cell engraftment depend on the levels of
anti-donor isoagglutinins and are efficiently prevented by the pretransplant removal of these
isoagglutinins. The benefits of reducing the time of transfusion-dependency and transfusion-associated
risks must be carefully balanced against the potential side effects of isoagglutinin reduction.
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Background
Persistent anti-donor isoagglutinins after major ABO blood group incompatible
hematopoietic stem cell transplantation may cause delayed red blood cell engraftment and
post-transplant pure red cell aplasia. 
Design and Methods
We investigated the effect of pretransplant anti-donor isoagglutinin reduction by in vivo ab-
sorption and/or plasmapheresis on the incidence of pure red cell aplasia and the time to
red blood cell engraftment in 153 hematopoietic stem cell transplant recipients with major
ABO incompatibility. 
Results
Twelve patients (8%) developed pure red cell aplasia, 3/98 (3%) with, and 9/55 (16%)
without prior isoagglutinin reduction (p=0.009). Red blood cell engraftment was faster in
patients with isoagglutinin reduction; in addition, peripheral blood hematopoietic stem
cell transplantation, acute graft-versus-host disease, and younger age were associated with
faster red blood cell engraftment in Cox regression analysis. In patients with pure red cell
aplasia the mean red blood cell engraftment occurred after 225 days (p<0.001) and was
associated with a simultaneous decrease of anti-donor isoagglutinins. Patients with pure
red cell aplasia had higher pretransplant anti-donor isoagglutinin titers (p=0.001) and
received more post-transplant red blood cell transfusions (p<0.001). 
Conclusions
Following major ABO incompatible hematopoietic stem cell transplantation, pure red cell
aplasia and delayed red blood cell engraftment depend on the levels of anti-donor isoag-
glutinins and are efficiently prevented by the pretransplant removal of these isoagglu-
tinins. The benefits of reducing the time of transfusion-dependency and transfusion-asso-
ciated risks must be carefully balanced against the potential side effects of isoagglutinin
reduction.
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transplantation, pure red cell aplasia.
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Introduction
Approximately 30-40% of all allogeneic hematopoiet-
ic stem cell transplants (HSCT) are ABO incompatible.1-3
These incompatibilities include major and bidirectional
ABO incompatibility, defined by the presence of isoag-
glutinins in the recipient against donor red blood cells
(RBC) and carry the risk of post-transplant hemolysis.
Whereas post-transplant hemolysis can be efficiently
prevented by the removal of RBC from the graft or by
reduction of anti-donor isoagglutinins from the recipi-
ent,3-6 there is no general consensus on the prophylactic
approach and the respective effect of pretransplant
isoagglutinin removal on RBC engraftment and pure red
cell aplasia (PRCA).7
Post-transplant PRCA is a hyporegenerative anemia
characterized by the absence of RBC precursors in the
bone marrow, and often requires RBC transfusions for a
prolonged period of time. Presumably, it is caused by the
destruction of RBC precursors through anti-donor isoag-
glutinins produced by persisting host plasma cells. We
hypothesized that pretransplant removal of anti-donor
isoagglutinins by plasmapheresis or transfusion of
donor-type ABO incompatible RBC (in vivo adsorption)
may facilitate RBC engraftment and consequently
reduce the incidence of PRCA. We, therefore, performed
a retrospective analysis of patients with major or bidi-
rectional ABO incompatible HSCT undergoing two dif-
ferent regimens: (i) pretransplant reduction of anti-donor
isoagglutinin titer and post-transplant transfusion of
donor-type RBC or (ii) removal of RBC from the graft
followed by post-transplant transfusion of recipient-
type RBC. In this cohort, the incidence and the risk fac-
tors of post-transplant PRCA and the time to RBC
engraftment were determined.
Design and Methods
Patients
A total of 153 consecutive patients receiving major
(n=123, 80%) or bidirectional (n=30, 20%) ABO incom-
patible allogeneic HSCT in two Swiss centers from
1980 to 2002 were retrospectively analyzed. All patients
gave written informed consent for retrospective data
analyses and the study was approved by the institution-
al review boards. The majority of the patients had been
transplanted for hematologic malignancies including
acute myelogenous leukemia (n=55, 36%), acute lym-
phoblastic leukemia (n=24, 16%), and chronic myeloge-
nous leukemia (n=40, 26%). Early disease was defined
as acute leukemia in complete first remission after
chemotherapy and chronic myelogenous leukemia in
first chronic phase (n=61, 40%). All other stages of
these malignancies and all other types of hematologic
cancers (n=82, 54%) were considered as advanced dis-
ease. Ten patients (6%) were transplanted for non-
malignant hematologic disorders. The median follow-
up time of the surviving patients was 70 months (range,
7-254). Seventy-four percent of the patients received
bone marrow and 26% peripheral blood stem cells.
Conventional myeloablative conditioning was used in
130/153 (85%) patients and consisted of cyclophos-
phamide and total body irradiation, cyclophos-
phamide/total body irradiation and etoposide, or busul-
fan/cyclophosphamide. The remaining patients (23,
15%) received reduced-intensity conditioning consist-
ing of fludarabine/total body irradiation, fludarabi-
ne/busulfan/antithymocyte globulin or cyclophos-
phamide with or without antithymocyte globulin.
Details of the transplant procedures are listed in Table 1.
Cyclosporine A combined with short-term methotrex-
ate (78, 51%) or cyclosporine A alone (n=69, 45%) was
administered for graft-versus-host disease (GvHD) pro-
phylaxis, the remaining six patients received other regi-
mens. Tapering of the immunosuppression was started
3-6 months after allogeneic HSCT if no signs of GvHD
were present and was reduced over a period of 3
months. First-line therapy for acute and chronic GvHD
was corticosteroids. In steroid-resistant cases,
daclizumab, methotrexate or OKT3 was administered
according to each center’s policy. Thirteen patients
received T-cell-depleted stem cells. The baseline charac-
teristics of patients who did or did not undergo anti-
donor isoagglutinin reduction are outlined in Table 1.
The two groups differed significantly with respect to
age of the patients, and the incidence and severity of
acute GvHD. In particular, patients who underwent
isoagglutinin reduction were younger and had a higher
incidence of acute GvHD. 
Anti-donor isoagglutinin reduction and transfusion
policies
Isoagglutinin reduction was performed by transfusion
of ABO incompatible, donor-type RBC (n=70, 46%),
plasmapheresis (n=6, 4%), or a combination of both
methods (n=22, 14%), as previously described.6,8 Most
of these patients were treated in one center (96/98,
98%), and received a median of three donor-type RBC
transfusions on 3 consecutive days, generally adminis-
tered during total body irradiation immediately before
HSCT. The aim was to lower the pretransplant isoagglu-
tinin titer to less than or equal to 1:2 and isoagglutinin
titers were measured daily during the procedure. To pre-
vent adverse reactions, the incompatible RBC were
transfused slowly over a period of 12 hours after admin-
istration of corticosteroids, prehydration with crystal-
loids followed by forced diuresis with furosemide and
mannitol. In general, the procedure was well tolerated,
but transfusion reactions including hemolysis, fever, rig-
ors, hematuria and lumbar pain were noted.
Plasmapheresis was performed on 3 consecutive days
directly prior to HSCT using a Cobe Spectra® cell sepa-
rator (Gambro BCT, Lakewood, CO, USA) by exchang-
ing one or two plasma volumes. Replacement fluids
were human albumin or fresh-frozen plasma in patients
with a history of bleeding. Patients with pretransplant
isoagglutinin reduction received post-transplant donor-
type RBC transfusions. In cases with post-transplant
hemolysis, transfusions were partially switched to recip-
ient-type RBC according to the physicians’ judgments.
All patients with clinically significant hemolysis received
recipient-type RBC transfusion as long as donor-specific
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PRCA and anti-donor isoagglutinin reduction
antibodies were measurable or any signs of hemolysis
were present.
In the remaining 55 patients who did not undergo
isoagglutinin reduction, post-transplant hemolysis was
prevented by removal of RBC from the graft. These
patients were treated predominantly in the second cen-
ter (44/55, 80%) and received exclusively recipient- or
O-type RBC transfusions as long as anti-donor isoagglu-
tinins were detectable or direct antiglobulin testing was
positive. All patients received RBC transfusions if their
hemoglobin concentration was less than 60-80 g/L or if
clinical signs of anemia were present. Donor-type RBC
chimerism was defined as the occurrence of a complete
ABO donor blood group type without any transfusion-
al support for at least 2 months.
Laboratory evaluations
During hospitalization, leukocyte and platelet counts
and hemoglobin concentration were determined daily,
while reticulocyte and differential leukocyte counts
were measured at least twice a week. After discharge,
these values were assessed on a weekly basis until day
100 and at least four times a year during long-term fol-
low-up. Isoagglutinin titers were determined by serial
dilution saline agglutination.9 Further laboratory evalua-
tions included measurements of creatinine, liver
enzymes, bilirubin, and lactate dehydrogenase. Post-
transplant PRCA was defined as anemia with low or
absent reticulocytes counts (<1%) in the peripheral
blood for more than 100 days in association with nor-
mal white blood cell and platelet engraftment. Bone
marrow examinations were routinely performed 3
months after HSCT, showing a lack of erythropoiesis in
the presence of normal myelo- and megakaryopoiesis in
all patients with PRCA. RBC engraftment was docu-
mented by the appearance of more than 1% reticulo-
cytes in the peripheral blood, platelet engraftment by
platelet counts greater than 50×109L for 3 days without
transfusion therapy, and neutrophil engraftment by
absolute neutrophil counts of more than 0.5×109/L for 3
days.
Statistical analysis and literature review
Means and proportions of baseline characteristics
were compared by Mann-Whitney U, Student’s t, and χ2
tests, as appropriate. Univariate risk factors for PRCA
were analyzed by logistic regression. The survival func-
tions were estimated with the method of Kaplan and
Meier and compared by the log rank test. The cumula-
Table 1A. Baseline characteristics of the patients.
Pretransplant anti-donor
isoagglutinin titer reduction
Yes No Total p
(n=98) (n=55) (n=153) value1
Patient age [years (range)] 28 34 30 0.006
(4-61) (3-61) (7-61)
Gender [number of patients (percent)] 0.926
Male 56 (57.1) 31 (56.4) 87 (56.9)
Female 42 (42.9) 24 (43.6) 66 (43.1)
Donor-recipient gender-match 0.573
Male-male 39 (39.8) 23 (41.8) 62 (40.5)
Male-female 14 (14.3) 12 (21.8) 26 (17.0)
Female-female 28 (28.6) 12 (21.8) 40 (26.1
Female-male 17 (17.3) 8 (14.5) 25 (16.3)
Matched related/unrelated donor 0.458
Matched related donor 75 (76.5) 42 (76.4) 117 (76.5)
Matched unrelated donor 15 (15.3) 11 (20.0) 26 (17.0)
HLA-mismatch 8 (8.2) 2 (3.6) 10 (6.5)
ABO match 0.347
Major 81 (82.7) 42 (76.4) 123 (80.4)
Bidirectional 17 (17.3) 13 (23.6) 30 (19.6)
Diagnosis 0.517
AML 36 (36.7) 19 (34.5) 55 (35.9)
ALL 16 (16.3) 8 (14.5) 24 (15.7)
CML 21 (21.4) 19 (34.5) 40 (26.1)
Lymphoma 7 (7.1) 4 (7.3) 11 (7.2)
MDS 7 (7.1) 3 (5.5) 10 (6.5)
SAA 8 (8.2) 1 (1.8) 9 (5.9)
Other 3 (3.1) 1 (1.8) 4 (2.6)
Disease stage 0.549
Non-malignant 8 (8.2) 2 (3.6) 10 (6.5)
Early disease 38 (38.8) 23 (41.8) 61 (39.9)
Advanced disease 52 (53.1) 30 (54.5) 82 (53.6)
Table 1B. Baseline characteristics of the patients.
Pretransplant anti-donor
isoagglutinin titer reduction
Yes No Total p
(n=98) (n=55) (n=153) value1
Conditioning2 0.124
Cy/TBI ± others 80 (81.6) 37 (67.3) 117 (76.5)
Bu/Cy 6 (6.1) 7 (12.7) 13 (8.5)
Reduced intensity 12 (12.2) 11 (20.0) 23 (15.0)
Stem cell source 0.534
Bone marrow 74 (75.5) 39 (70.9) 113 (73.9)
Peripheral blood 24 (24.5) 16 (29.1) 40 (26.1)
Total nucleated cells3 3.7 3.2 3.7
(0.3-30.7) (0.4-15.9) (0.3-30.7) 0.258
Hemolysis 0.090
No 54 (55.1) 38 (69.1) 92 (60.1
Yes 44 (44.9) 17 (30.9) 61 (39.9)
GvHD prophylaxis 0.606
CsA 47 (48.0) 22 (40.0) 69 (45.1)
CsA/MTX 47 (48.0) 31 (56.4) 78 (51.0)
Others 4 (4.1) 2 (3.6) 6 (3.9)
T-cell depletion 0.771
No 89 (90.8) 51 (92.7) 140 (91.5)
Yes 9 (9.2) 4 (7.3) 13 (8.5)
Acute GvHD 0.012
No 24 (24.5) 24 (43.6) 48 (31.4)
Grade I 20 (20.4) 17 (30.9) 37 (24.2)
Grade II 29 (29.6) 7 (12.7) 36 (23.5)
Grade III 12 (12.2) 4 (7.3) 16 (10.5)
Grade IV 13 (13.3) 3 (5.5) 16 (10.5)
1Differences among the groups were analyzed by χ2,Mann-Whitney U,or Student’s t tests, as
appropriate, 2Myeloablative conditioning:Cy/TBI,Cy/VP16/TBI,Cy/VP16/ATG/TBI,Reduced
intensity conditioning: Flu/Bu/ATG,Flu/TBI,Cy±ATG. 3Median total nucleated cell x108/kg
body weight.AML: acute myelogenous leukemia; ALL: acute lymphoblastic leukemia; CML:
chronic myelogenous leukemia; MDS: myelodysplastic syndrome; SAA: severe aplastic ane-
mia; Cy: cyclophosphamide;TBI: total body irradiation; Bu: busulfan;VP16: etoposide; ATG:
antithymocyte globulin; Flu: fludarabine; CsA: cyclosporine A; MTX: methotrexate.
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tive incidence of PRCA was calculated using death with-
out RBC engraftment as a competing risk. Cox propor-
tional hazards regression models were used for the mul-
tivariate analysis of risk factors for RBC engraftment. To
account for onset times of acute GvHD a proportional
hazards regression model was built using a time-
dependent covariate for acute GvHD in such a way that
patients were in the group without acute GvHD at the
time of transplant and switched to the group with acute
GvHD at the time of onset of this complication.
Covariates (age, disease stage, HLA match, year of trans-
plantation, gender mismatch, conditioning, and GvHD
prophylaxis) were entered in a forward stepwise fash-
ion. All reported p values are two-sided, and p value less
than 0.05 were assumed to be statistically significant. 
To identify previously published case reports and case
series with post-transplant PRCA a Pubmed search was
carried out using the MESH terms red cell aplasia or
PRCA, HSCT or stem cell transplantation, and ABO blood
group. Only articles written in English were considered
for the analysis. Case series were defined as reports on
PRCA patients with an appropriate control group (major
ABO incompatible patients without PRCA) allowing
incidence calculation.
Results
Post-transplant pure red cell aplasia
Twelve out of 153 (8%) patients who received ABO
incompatible transplants developed post-transplant
PRCA. PRCA was self-limiting and all patients ultimate-
ly became transfusion-independent. Figure 1A shows
the time to RBC engraftment of all patients with PRCA
(mean 225 days, 95%-CI 180-270) compared to that in
the 141 patients without PRCA (mean 25 days, 95%-CI
22-27) (p<0.001). The median anti-donor isoagglutinin
titer in patients with PRCA was 1:64 (range, 1:32-1:1024)
compared to 1:16 (range, 1:1-1:1024) in patients without
PRCA (p=0.001). PRCA was observed exclusively in
patients with anti-donor isoagglutinin titers greater than
1:16. It occurred in 3/98 (3%) patients who had under-
gone anti-donor isoagglutinin reduction and in 9/55
(16%) who had not (p=0.009). Figure 2 outlines the
reduction of isoagglutinins by in vivo adsorption, plasma-
pheresis or a combination of both methods.
Isoagglutinins were reduced by a median of five titer
steps from 1:32 to 1:1 (p<0.001). The adsorption capaci-
G. Stussi et al. 
Figure 1. Cumulative incidence of PRCA and RBC engraftment (A)
Incidence of PRCA. Mean time to RBC engraftment was later in
patients with PRCA (dotted lines, n=12) (225 days; 95%-CI 180-
270) than in patients without PRCA (solid lines, n=141) (25 days;
95%-CI 22-27) (p<0.001). (B) RBC engraftment in all patients with
major or bidirectional ABO incompatible HSCT (n=153). Patients
who had undergone anti-donor isoagglutinin reduction (solid lines,
n=55) had faster RBC engraftment (p<0.001) than patients who
had not undergone such reduction (dotted lines, n=98). (C) RBC
engraftment after exclusion of the 12 patients with PRCA. The
delayed in RBC engraftment was still evident after exclusion of all
patients with PRCA (p=0.037).
Figure 2. Pretransplant anti-donor isoagglutinin reduction. Box
plots represent median values of agglutination titers before
(white) and after (gray) isoagglutinin reduction. Isoagglutinins
were not reduced (No) or reduced by plasmapheresis (PP), in vivo
adsorption (IVA) or a combination of both techniques (IVA/PP).
The median anti-donor isoagglutinin titer in recipients of major
ABO incompatible HSCT was 1:32 before and 1:1 after the reduc-
tion of anti-donor isoagglutinins (p<0.001). The adsorption capac-
ity of the different procedures was similar, but the combination of
IVA and PP was used more often in patients with higher titers.
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ty was similar with the different procedures, but the
combination of in vivo adsorption and plasmapheresis
was used more often in patients with higher titers. 
The clinical details of all patients with PRCA are list-
ed in Table 2. All 12 patients with PRCA had blood
group O and had received a major ABO incompatible
HSCT from a blood group A (n=10), AB (n=1), or B
(n=1) donor. No case of PRCA was observed after bidi-
rectional ABO incompatible HSCT. Presumably, this
difference can be attributed to the lower pretransplant
isoagglutinin titers in the group of patients with bidirec-
tional ABO incompatibility (bidirectional incompatibili-
ty: median 1:16; range 1:1-1:256 vs. major incompatibil-
ity: median 1:32; range 1:1-1:1024; p=0.012). The three
patients with PRCA despite anti-donor isoagglutinin
reduction had a shorter time to RBC engraftment (143,
147 and 157 days) than the nine patients without titer
reduction. Patients with PRCA received more RBC
transfusions (mean 36, range 12-60 vs. 12, range 0-59;
p<0.001). In 11 patients, resolution of PRCA was pre-
ceded by a spontaneous decrease of anti-donor isoag-
glutinins to titers less than 1:8, whereas one patient
recovered from PRCA despite persistently elevated anti-
donor isoagglutinins. In this patient, a relapse of the
underlying disease was diagnosed shortly after recovery
from PRCA and the increase of hemoglobin was caused
by recipient-type RBC. Ten patients with PRCA eventu-
ally achieved complete donor-type RBC chimerism.
Two patients never had a complete switch to donor-
type RBC in the peripheral blood, one because of
relapse and the other because of death due to acute
grade IV GvHD. Two patients had late-onset acute
GvHD. One patient received reduced intensity condi-
tioning and HSCT and developed grade IV acute GvHD
1 month after tapering off immunosuppression. In this
patient, the resolution of PRCA was associated with the
onset of acute GvHD. The second patient experienced a
late relapse after HSCT which was treated with rein-
duction chemotherapy followed by donor-lymphocyte
infusion. Eighty-seven days after donor lymphocyte
infusion he developed a therapy-refractory grade IV
acute GvHD of the liver and the skin and died 142 days
after infusion of the donor lymphocytes. 
The risk factors for PRCA were analyzed by univari-
ate logistic regression (Table 3). Patients who under-
went isoagglutinin reduction were less likely to develop
PRCA (odds ratio 0.16, 95%-CI 0.04-0.63, p=0.008),
whereas HSCT recipients from A or AB donors were at
greater risk (odds ratio 9.96, 95%-CI 1.25-79.21,
p=0.039). Patients with acute GvHD grades II-IV
showed a trend toward a lower incidence of PRCA
(odds ratio 0.23, 95%-CI 0.05-1.07, p=0.062) and
patients older than the mean age at HSCT showed a
trend toward a higher incidence of PRCA (odds ratio
3.61, 0.94-13.89, p=0.062). However, neither of these
tendencies was statistically significant.
Hematopoietic engraftment
Eight patients did not achieve RBC engraftment
because of early transplant-related death (5%) with a
median survival time of 12 days (range, 6-37 days). The
mean time to RBC engraftment in the remaining
Table 2. Clinical course of patients with PRCA.
Patient - UPN 39 40 49 106 149 153 177 231 252 684 808 887
ABO (D/R) A/O A/O A/O A/O A/O A/O A/O A/O A/O A/O AB/O B/O
Age at HSCT 37 36 14 34 26 41 51 43 39 53 26 40
Gender (D/R) F/F M/F M/M M/M F/M M/M M/M M/M F/M M/M F/F M/M
Year of HSCT 86 86 87 92 96 96 98 00 01 98 00 01
Disease AML CML ALL CML CML CML CML AML NHL CIMF CML AML
Disease stage1 II II II I I I I II II II II I
Conditioning Cy/TBI Cy/TBI Cy/VP16 Bu/Cy Cy/TBI Bu/Cy Bu/Cy Cy/TBI Flu/Bu Cy/VP16 Cy/VP16 Cy/TBI
/TBI /ATG /TBI /TBI
HLA match MRD MRD MRD MRD MRD MRD MRD MUD MRD MRD MRD MRD
Stem cell source BM BM BM BM BM BM BM BM PB PB BM PB
GvHD prophylaxis CsA CsA CsA CsA/MTX CsA/MTX CsA/MTX CsA/MTX CsA/MTX CsA/MTX CsA/MTX CsA/MTX CsA/MTX
Acute GvHD2 0 I (12) I (10) I (36) 0 I (24) 0 IV (708) IV (193) 0 I (33) 0
Isoagglutinin reduction No No No No No No No No No PP/IVA PP/IVA IVA
Isoagglutinins3 1:1024 1:32 1:64 1:64 1:128 ND ND 1:64 1:64 1:256/1:2 1:256/1:4 1:32/1:1
IAT decrease (days) 229 180 148 NR 213 188 346 173 166 139 125 157
Transfusions (n/days) 29/250 22/190 12/118 55/370 52/259 32/175 52/353 60/228 36/350 27/179 43/213 16/74
RBC take/chimerism4 245/Yes 181/Yes 148/Yes 382/No 256/Yes 222/Yes 346/Yes 214/Yes 203/No 147/Yes 143/Yes 157/Yes
Outcome (months) CR Rel (18) CR Rel (17) CR CR CR Rel (17) GvHD Rel (40) CR CR
Follow up (months) 122 34 129 167 36 24 30 25/Death 12/Death 41/Death 12 36
AML: acute myelogenous leukemia; ALL: acute lymphatic leukemia; ATG: antithymocyte globulin; B: busulfan; CIMF: chronic idiopathic myelofibrosis; CML: chronic myelogenous
leukemia; CR: complete remission; CsA: cyclosporine A; Cy: cyclophosphamide; Flu: fludarabine; IVA, in vivo adsorption; MRD,matched related donor; MTX: methotrexate; MUD:
matched unrelated donor; ND: not determined; NHL: non-Hodgkin lymphoma; PP: plasmapheresis; Rel, relapse;TBI: total body irradiation;VP16: etoposide. 1non malignant disease,0;
early disease stage, I; advanced disease stage II, 2Grade (day of onset). 3Pretransplant anti-donor isoagglutinin titer before and after titer reduction. 4Donor-type RBC chimerism was
defined as the occurrence of a complete donor blood group type without any transfusional support for at least 2 months.
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patients was 42 days (95%-CI 32-53). Neutrophil
engraftment was reached after 17 days (95%-CI 16-19)
and platelet engraftment after 32 days (95%-CI 27-38)
without differences between the groups (p=0.379 and
p=0.364, respectively). As shown in Figure 1B, patients
who underwent anti-donor isoagglutinin reduction had
faster RBC engraftment (p<0.001). This difference also
persisted after exclusion of all patients with PRCA
(mean 23 days, 95%-CI 21-26 vs. 28 days; 95%-CI 23-
33; p=0.037; Figure 1C). Isoagglutinin reduction, bidi-
rectional ABO incompatibility, HSCT using peripheral
blood stem cells, younger age of the recipient at trans-
plantation, reduced-intensity conditioning regimens,
and the occurrence of acute grade II-IV GvHD signifi-
cantly reduced the time to RBC engraftment according
to the results of a Cox regression analysis (Table 4). In
contrast, the number of stem cells in the graft, the year
of HSCT, the conditioning regimen, gender mismatch,
or GvHD prophylaxis did not influence RBC engraft-
ment. Cyclosporine A as a single agent for GvHD pro-
phylaxis has been described as a risk factor for the
development of PRCA and delayed RBC engraftment.
However, in this study, the distribution of the two
GvHD prophylaxis regimens was similar among
patients with and without PRCA and GvHD prophylax-
is did not influence the time to RBC engraftment. 
Discussion
The present study documents a protective effect of
pretransplant anti-donor isoagglutinin reduction on the
development of delayed RBC engraftment and post-
transplant PRCA following major or bidirectional ABO
incompatible HSCT. PRCA occurred in 3% of patients
who underwent isoagglutinin reduction and in 16%
who did not. As previously reported the importance of
anti-donor isoagglutinins for the occurrence of post-
transplant PRCA was supported by a clear association
between the recovery of reticulocytes and the decrease
of anti-donor isoagglutinins in 11/12 patients with
PRCA.10 In the remaining patient re-emergence of RBC
hematopoiesis occurred despite persistently elevated
anti-donor isoagglutinins and relapse was later diag-
nosed. Thus, RBC engraftment represented host rather
than donor RBC erythropoiesis and was the first sign of
relapse. 
As observed by others, the threshold of anti-donor
isoagglutinin titers necessary for successful donor-type
RBC engraftment ranged from 1:8 and 1:2.11,12 In line
with these data, nearly all published cases of post-trans-
plant PRCA were reported by centers that did not use
pretransplant isoagglutinin reduction.13-15 In the few
studies in which PRCA occurred despite isoagglutinin
reduction, a rebound of anti-donor isoagglutinins sug-
gests post-transplant transfusion of recipient-type
RBC.16 If the isoagglutinins are only temporarily
removed prior to the HSCT, they may rebound soon
after transplantation to an even higher level.17 In con-
trast, pretransplant anti-donor isoagglutinin reduction
by the above mentioned strategies in combination with
post-transplant transfusion of donor-type RBC may
provide a durable suppression of anti-donor isoagglu-
tinins and facilitate RBC engraftment. In conclusion, the
combination of pretransplant reduction of isoagglutinin
titers and the at least partial post-transplant transfusion
of donor-type RBC appears to be crucial for the preven-
tion of PRCA. 
Table 4. Cox regression analysis of red blood cells engraftment.
Variable Hazard ratio 95%-CI p value
ABO incompatibility
Major 1.00 – –
Bidirectional 1.97 1.26-3.06 0.003
Isoagglutinin titer reduction1
No 1.00 – –
Yes 1.57 1.05-2.35 0.029
Acute GvHD2
Grade 0-I 1.00 – –
Grade II-IV 1.79 1.19-2.70 0.050
Stem cell source
Bone marrow 1.00 – –
Peripheral blood 2.18 1.41-3.38 <0.001
Conditioning
Myeloablative 1.00 – –
Reduced intensity 1.81 1.08-3.03 0.025
Age at HSCT3 0.99 0.97-1.00 0.032
1Anti-donor isoagglutinin titer reduction: in vivo adsorption,plasmapheresis, or both
methods. 2Acute GvHD was analyzed as a time-dependent covariate. 3Increment=1
year.
Table 3. Univariate risk factor analysis for pure red cell aplasia.
Risk factors Odds ratio 95%-CI p value1
Isoagglutinin reduction
No 1.00
Yes 0.16 0.04-0.63 0.008
Acute GvHD
Grade 0-I 1.00
Grade II-IV 0.23 0.05-1.07 0.062
GvHD prophylaxis2
CsA/MTX 1.00
CsA 1.86 0.53-6.46 0.331
Blood group constellation
A or AB donor to O recipient 9.96 1.25-79.21 0.039
Other combinations 1.00
Conditioning
Myeloablative 1.00
Non-myeloablative 0.49 0.06-4.00 0.507
Stem cell source
Bone marrow 1.00
Peripheral blood 0.94 0.24-3.65 0.925
Age at HSCT
Below mean age 1.00
above mean age 3.61 0.94-13.89 0.062
Rhesus compatibility
Compatible 1.00
Incompatible 0.44 0.05-3.61 0.446
Donor type3
Matched related 1.00
Matched unrelated 0.38 0.05-3.13 0.372
1Univariate risk factors were analyzed by logistic regression. 2Six patients with
alternative GvHD prophylaxis were excluded: 3Ten patients with HLA-mismatches
were excluded.
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Although the mechanism of post-transplant PRCA is
not fully understood, it is believed that the persistence
of host B lymphocytes or plasma cells producing anti-
donor isoagglutinins is responsible for the delayed
engraftment.12 In support of this hypothesis, autolo-
gous plasma derived from patients with PRCA inhibits
donor-type erythropoiesis in vitro.18-20 In contrast, early
erythroid progenitors can engraft at the same rate as
myeloid progenitors measured by erythroid burst
forming unit assays, indicating that ABO antigens are
acquired at a later stage of erythroid commitment.21
Moreover, mixed chimerism analyses of hematopoietic
cells after HSCT demonstrated temporal differences in
the post-transplant eradication of recipient cells with a
persistence of plasma cells for up to 9 months.12
In the present study the overall incidence of post-
transplant PRCA was 8% and this complication
occurred after major but not bidirectional ABO incom-
patible HSCT. The only two risk factors identified were
a lack of pretransplant isoagglutinin reduction and the
blood group constellation A or AB donor into an O
group recipient. A review of the published literature
identified 128 patients with PRCA in 18 case
series11–13,15,20-33 and 35 case reports16,18,19,34-66 with an over-
all incidence of 15% (range, 2-50%).12,22 However, this
may overestimate the true incidence due to a publica-
tion bias. The most frequent blood group constellation
was A or AB donor and O group recipient, occurring in
77% of all patients. The higher incidence of PRCA in
recipients with anti-A isoagglutinins may be explained
by the higher levels and the longer persistence of anti-
A antibodies as compared to anti-B antibodies.25 Major
ABO-incompatibility was the most common risk factor
described in 120 patients, bidirectional ABO incompat-
ibility was found in 5 patients.16,25,37 Two of the remain-
ing three patients developed PRCA after ABO compat-
ible HSCT41,49 and one after autologous HSCT.39 No
clear explanation was found for the PRCA in these
patients. Anti-donor isoagglutinin titers were reported
in most of the publications. The median titers were
1:128 (1:2-1:4096) for IgM and 1:512 (1:2-1:16000) for
IgG, but the titers were evaluated using a variety of dif-
ferent techniques. Most authors suggested high pre-
transplant isoagglutinin titers as a cause of the observed
PRCA, but none of the case series could clearly estab-
lish a correlation between the incidence of PRCA and
the titer levels. Parvovirus B19 infection has been
shown to be responsible for PRCA after allogeneic or
autologous HSCT.67-69 However, in a large series of 201
adult patients who underwent allogeneic HSCT, no
parvovirus B19 infections occurred in the first year and
only three cases were detected in the second year after
HSCT.70 It, therefore, seems unlikely that parvovirus
B19 infections are primarily responsible for post-trans-
plant PRCA, although this was not routinely analyzed
in our cohort of patients. 
The roles of reduced intensity conditioning and the
number of transplanted cells in the pathogenesis of
post-transplant PRCA are still controversial. Although
several publications have reported on the occurrence of
PRCA after reduced intensity conditioning transplants,
with an incidence ranging from 2-50%, it is difficult to
draw definitive conclusions as they described very het-
erogeneous populations.12,20,21,27,31,71 In theory, condition-
ing protocols of lower intensity and GvHD prophylax-
is regimens could lead to a higher incidence of post-
transplant PRCA because of less activity against plasma
cells. In our cohort, however, we did not find a higher
incidence of PRCA in the small group of patients who
received reduced intensity conditioning and the time to
RBC engraftment was similar in the groups conditioned
with reduced intensity or myeloablative regimens. 
The eradication of recipient-type plasma cells after
allogeneic HSCT depends on a graft-versus-plasma cell
effect. This was demonstrated by Mielcarek et al. who
showed that donor-specific isoagglutinins disappear
more rapidly in the case of matched unrelated donors
than matched related donors and patients with acute
GvHD had a more rapid clearance of isoagglutinins in
both groups.72 In the present study, 7/12 patients with
post-transplant PRCA developed acute GvHD, but only
in one patient was the resolution of PRCA related to
the onset of GvHD. However, the majority of patients
had only mild acute GvHD, which may not have been
sufficient to overcome PRCA. Moreover, although sev-
eral case reports suggested such an association, it was
not confirmed by any of the case series.30, 49 In support
of the findings of Mielcarek et al., we observed that
both the occurrence of acute GvHD and isoagglutinin
reduction were associated with a shorter time to RBC
engraftment in patients with major ABO incompatible
HSCT. In contrast, faster RBC engraftment in patients
who underwent GvHD was not observed after ABO-
identical HSCT (data not shown). Finally, the use of
cyclosporine A alone without methotrexate for GvHD
prophylaxis has been associated with delayed RBC
engraftment or hemolysis.23,73 Since methotrexate has a
clear immunosuppressive effect on B-lymphocytes and
antibody production, it might reduce the isoagglutinin
titers after HSCT. However, in our study, we did not
observe a difference in the incidence of PRCA and
delayed RBC engraftment depending on whether
methotrexate was or was not administered. 
The first therapeutic approach to overcome post-
transplant PRCA is the reduction or withdrawal of
immunosuppression to enhance the graft-versus-plas-
ma cell effect.48,49 If this strategy is not successful, sev-
eral other strategies have been proposed according to
the pathophysiology of the disorder: plasmaphere-
sis,43,46,64 antithymocyte globulin,38,41 erythropoi-
etin,39,42,44,61 corticosteroids,53,56 rituximab,47,54 and donor-
lymphocyte infusions to induce GvHD.45,51 Virtually all
of these treatments have only been evaluated in a few
patients or in single case reports. In our cohort, one
patient was treated with plasmapheresis without clini-
cal improvement; all other patients received supportive
treatment with RBC transfusions and iron chelation if
necessary. Anti-donor isoagglutinins eventually disap-
peared in all but one patient without specific measures.
The spontaneous antibody clearance may reflect the
approximate lifetime of recipient plasma cells or the
eradication of the remaining plasma cells by the donor
immune system. Since the best treatment for patients
with PRCA is unknown, the potential side effects of
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